PL3625222T3 - Pochodne fenylu jako modulatory receptora pge2 - Google Patents

Pochodne fenylu jako modulatory receptora pge2

Info

Publication number
PL3625222T3
PL3625222T3 PL18725222T PL18725222T PL3625222T3 PL 3625222 T3 PL3625222 T3 PL 3625222T3 PL 18725222 T PL18725222 T PL 18725222T PL 18725222 T PL18725222 T PL 18725222T PL 3625222 T3 PL3625222 T3 PL 3625222T3
Authority
PL
Poland
Prior art keywords
receptor modulators
phenyl derivatives
pge2 receptor
pge2
phenyl
Prior art date
Application number
PL18725222T
Other languages
English (en)
Inventor
Christoph Boss
Olivier Corminboeuf
Heinz Fretz
Isabelle Lyothier
Davide Pozzi
Sylvia Richard-Bildstein
Hervé SIENDT
Thierry Sifferlen
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3625222T3 publication Critical patent/PL3625222T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PL18725222T 2017-05-18 2018-05-17 Pochodne fenylu jako modulatory receptora pge2 PL3625222T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017062031 2017-05-18
EP18725222.6A EP3625222B1 (en) 2017-05-18 2018-05-17 Phenyl derivatives as pge2 receptor modulators
PCT/EP2018/062862 WO2018210994A1 (en) 2017-05-18 2018-05-17 Phenyl derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
PL3625222T3 true PL3625222T3 (pl) 2021-12-27

Family

ID=62186480

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18725222T PL3625222T3 (pl) 2017-05-18 2018-05-17 Pochodne fenylu jako modulatory receptora pge2

Country Status (32)

Country Link
US (1) US11712438B2 (pl)
EP (1) EP3625222B1 (pl)
JP (1) JP7159214B2 (pl)
KR (1) KR102632028B1 (pl)
CN (1) CN110612296A (pl)
AR (1) AR111941A1 (pl)
AU (1) AU2018269666B2 (pl)
BR (1) BR112019024109A2 (pl)
CA (1) CA3060597A1 (pl)
CL (1) CL2019003275A1 (pl)
CO (1) CO2019010578A2 (pl)
CR (1) CR20190559A (pl)
CY (1) CY1124608T1 (pl)
DK (1) DK3625222T3 (pl)
EA (1) EA201992676A1 (pl)
ES (1) ES2893452T3 (pl)
HR (1) HRP20211533T1 (pl)
HU (1) HUE056080T2 (pl)
IL (1) IL270623B2 (pl)
LT (1) LT3625222T (pl)
MA (1) MA49126B1 (pl)
MX (1) MX388256B (pl)
PE (1) PE20191814A1 (pl)
PH (1) PH12019502563A1 (pl)
PL (1) PL3625222T3 (pl)
PT (1) PT3625222T (pl)
RS (1) RS62440B1 (pl)
SG (1) SG11201908729UA (pl)
SI (1) SI3625222T1 (pl)
TW (1) TWI765041B (pl)
UA (1) UA125123C2 (pl)
WO (1) WO2018210994A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
WO2019136320A1 (en) 2018-01-05 2019-07-11 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
EP3906028A4 (en) * 2018-12-31 2022-10-12 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
WO2022272062A1 (en) 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU3445100A (en) 2000-03-24 2001-10-08 Pharmagene Lab Ltd Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
WO2003086390A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
WO2003087061A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
JP2006506327A (ja) 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
ES2308139T3 (es) 2003-01-29 2008-12-01 Asterand Uk Limited Antagonista de receptos ep4.
CA2536887C (en) 2003-08-26 2012-03-06 Teijin Pharma Limited Pyrrolopyrimidinone derivatives
CN1867551B (zh) 2003-09-03 2013-09-11 拉夸里亚创药株式会社 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
CN1950333A (zh) 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP2013169B1 (en) 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
EP2054401B1 (en) 2006-08-11 2013-05-01 Merck Canada Inc. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
JPWO2008123207A1 (ja) 2007-03-26 2010-07-15 アステラス製薬株式会社 オルニチン誘導体
US8003661B2 (en) 2007-03-26 2011-08-23 Merck Canada Inc. Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
CA2737618A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
WO2011063181A1 (en) 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
CA2806121C (en) 2010-09-21 2018-10-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
JP5273689B2 (ja) 2010-09-29 2013-08-28 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
JP2013542967A (ja) 2010-11-17 2013-11-28 ノバルティス アーゲー ３−（アミノアリール）−ピリジン化合物
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
WO2012149528A1 (en) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
WO2012177618A1 (en) 2011-06-20 2012-12-27 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
EP2729445B1 (en) 2011-07-04 2015-10-21 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor antagonists
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
JP6378171B2 (ja) * 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US9604937B2 (en) 2012-11-27 2017-03-28 Thomas Helledays Stiftelse For Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
EA028604B1 (ru) 2013-05-30 2017-12-29 Идорсиа Фармасьютиклз Лтд. Модуляторы рецептора cxcr7
HRP20180703T1 (hr) 2013-06-12 2018-06-15 Kaken Pharmaceutical Co., Ltd. Derivat 4-alkinil imidazola i lijek koji kao aktivni sastojak sadrži isti
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
PT3057959T (pt) * 2013-10-17 2018-06-04 Vertex Pharma Inibidores de adn-pk
CN105793236B (zh) 2013-12-17 2017-10-10 伊莱利利公司 二甲基苯甲酸化合物
ME02896B (me) 2013-12-17 2018-04-20 Lilly Co Eli Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
WO2015167825A1 (en) 2014-04-29 2015-11-05 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
KR102535283B1 (ko) 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
NZ733575A (en) 2015-01-09 2022-10-28 Ono Pharmaceutical Co Tricyclic spiro compound
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3484870B1 (en) 2016-07-13 2022-11-16 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives

Also Published As

Publication number Publication date
IL270623B (en) 2022-11-01
TW201900175A (zh) 2019-01-01
MA49126B1 (fr) 2021-10-29
LT3625222T (lt) 2021-11-10
US20200179383A1 (en) 2020-06-11
IL270623B2 (en) 2023-03-01
CO2019010578A2 (es) 2019-10-09
UA125123C2 (uk) 2022-01-12
PE20191814A1 (es) 2019-12-27
AU2018269666B2 (en) 2022-02-03
BR112019024109A2 (pt) 2020-06-02
EP3625222A1 (en) 2020-03-25
PT3625222T (pt) 2021-10-07
PH12019502563A1 (en) 2020-07-20
HRP20211533T1 (hr) 2022-01-07
TWI765041B (zh) 2022-05-21
EP3625222B1 (en) 2021-07-21
US11712438B2 (en) 2023-08-01
SI3625222T1 (sl) 2021-11-30
CN110612296A (zh) 2019-12-24
MA49126A (fr) 2020-03-25
KR102632028B1 (ko) 2024-01-31
AR111941A1 (es) 2019-09-04
SG11201908729UA (en) 2019-10-30
IL270623A (pl) 2019-12-31
RS62440B1 (sr) 2021-11-30
CL2019003275A1 (es) 2020-05-04
ES2893452T3 (es) 2022-02-09
WO2018210994A1 (en) 2018-11-22
HUE056080T2 (hu) 2022-01-28
JP7159214B2 (ja) 2022-10-24
DK3625222T3 (da) 2021-10-25
EA201992676A1 (ru) 2020-05-06
CA3060597A1 (en) 2018-11-22
AU2018269666A1 (en) 2020-01-16
CR20190559A (es) 2020-02-10
MX388256B (es) 2025-03-19
KR20200010352A (ko) 2020-01-30
JP2020520356A (ja) 2020-07-09
MX2019013718A (es) 2020-01-30
CY1124608T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
IL270620A (en) Pyrimidine history as PGE2 receptor modulators
ZA201906104B (en) Substituted imidazo-quinolines as nlrp3 modulators
HUE056080T2 (hu) Fenilszármazékok mint PGE2 receptor modulátorok
IL259424B (en) Nitrogen-substituted indole derivatives as pge2 receptor modulators
SI3507276T1 (sl) Spojine modulatorja toličnih receptorjev
MA43382A (fr) Modulateurs des récepteurs des chimiokines
EP3186225A4 (en) Cannabinoid type 1 receptor modulators
GB201716468D0 (en) Modulators
HUE042559T2 (hu) Hidroxialkil-piperazin származékok mint cxcr3 receptor modulátorok
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
ZA201803520B (en) Indane derivatives as mglur7 modulators
GB2563095B (en) Modulators
ZA201804099B (en) N-substituted indole derivatives as pge2 receptor modulators
HK1260563A1 (en) N-substituted indole derivatives as pge2 receptor modulators
GB201616065D0 (en) Receptor modulator compounds
GB201616071D0 (en) Receptor modulator compounds
GB201616072D0 (en) Receptor modulator compounds
GB201702926D0 (en) Modulators
GB201512714D0 (en) Receptor modulator compounds
HK1240212A1 (en) Substituted bridged urea analogs as sirtuin modulators